Taro Pharmaceutical Industries (NYSE:TARO) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO) in a research report released on Saturday. The brokerage issued a strong-buy rating on the stock.

Separately, HC Wainwright cut shares of Taro Pharmaceutical Industries from a buy rating to a neutral rating and set a $43.00 target price on the stock. in a research report on Thursday, January 18th.

Taro Pharmaceutical Industries Stock Performance

NYSE TARO opened at $42.51 on Friday. The company has a fifty day moving average of $42.15 and a 200-day moving average of $40.16. Taro Pharmaceutical Industries has a 52-week low of $24.69 and a 52-week high of $45.76. The company has a market capitalization of $1.60 billion, a P/E ratio of 34.84 and a beta of 0.61.

Hedge Funds Weigh In On Taro Pharmaceutical Industries

Hedge funds have recently modified their holdings of the company. Harvest Management LLC boosted its position in Taro Pharmaceutical Industries by 3.9% during the 4th quarter. Harvest Management LLC now owns 7,380 shares of the company’s stock valued at $308,000 after acquiring an additional 274 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Taro Pharmaceutical Industries by 1.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 22,223 shares of the company’s stock valued at $838,000 after acquiring an additional 307 shares during the period. SG Americas Securities LLC boosted its stake in Taro Pharmaceutical Industries by 24.5% during the fourth quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock worth $195,000 after acquiring an additional 921 shares in the last quarter. Strs Ohio grew its holdings in Taro Pharmaceutical Industries by 58.8% in the third quarter. Strs Ohio now owns 2,700 shares of the company’s stock worth $101,000 after purchasing an additional 1,000 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Taro Pharmaceutical Industries during the third quarter valued at approximately $65,000. Hedge funds and other institutional investors own 91.40% of the company’s stock.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.